Mexico Continuous Glucose Monitoring Market Size and Share
Mexico Continuous Glucose Monitoring Market Analysis by Mordor Intelligence
The Mexico Continuous Glucose Monitoring Market size is expected to grow from USD 167.08 million in 2026 to USD 187.11 million in 2027 and is forecast to reach USD 329.61 million by 2032 at 11.99% CAGR over 2027-2032.
During the COVID-19 pandemic, patients with diabetes were at higher risk for hospitalizations and complications due to hyper- or hypoglycemia, metabolic comorbidities, and more severe illness from SARS-CoV-2 infection. Maintaining euglycemia was important to decrease morbidity and mortality in the hospital setting. The Food and Drug Administration (FDA) allowed the use of CGM devices in the inpatient setting in response to the COVID-19 pandemic. According to experts, inpatient use of diabetes technology in patients with proper institutional protocols was safe and improved inpatient glycemic outcomes and played a vital role in managing hypoglycemia and hyperglycemia in hospitalized patients.
Regular and timely blood glucose monitoring enables the effective management of abnormal glucose levels and reduces the risk of diabetes-related complications. Prolonged high blood glucose levels in individuals with diabetes may result in progressive complications, such as kidney, nerve, and eye damage. Measuring blood glucose helps evaluate glucose metabolism and facilitates the maintenance of optimal glucose levels in the body. Over time, these measurements provide patients and healthcare professionals with the insights needed to develop an appropriate diabetes management plan.
Furthermore, continuous glucose monitoring (CGM) devices can review historical blood glucose patterns through data downloads or deliver real-time glucose readings on receiver displays. Recent CGM products, such as the Abbott FreeStyle Libre 3 and Dexcom G7, have addressed several technical limitations. Innovations such as the Eversense E3 CGM have substantially enhanced diabetes management for healthcare providers and patients, supporting favorable market growth prospects in the coming years.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Mexico Continuous Glucose Monitoring Market Trends and Insights
Rising Diabetes Prevalence in Mexico
The Mexican diabetes population is expected to rise by about 3.4% over the forecast period.
According to IDF Diabetes Atlas's latest estimates, the prevalence of diabetes in Mexico reached 16.9%, or one in six adults. An estimated 14.1 million adults in Mexico are living with diabetes. Additionally, 11 million adults in the country have Impaired Glucose tolerance, which places them at high risk of developing type 2 diabetes. Diabetes-related health expenditure in Mexico has reached USD 19.9 billion, putting it in the top ten countries with the highest total health expenditure. About 47.5% of people living in Mexico with diabetes are undiagnosed.
Lack of health insurance deprives people of access to services and puts them at risk of financial hardship. To protect the people against excessive health expenditures, Mexico has implemented mechanisms such as community-based health insurance, national health insurance, and targeted public health insurance. Mexico has multiple health insurance providers. The Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (State Employee’s Social Security and Social Services Institute, ISSSTE) provides coverage for government employees, and the Instituto Mexicano del Seguro Social (Mexican Social Security Institute, IMSS) covers for private-sector employees. The Seguro Popular (People’s Insurance) was launched to protect the working-age population against steep healthcare costs. Enrolment in the Seguro Popular is independent of health status or pre-existing illness; there is no co-payment by the type of health care received, and family contributions are determined solely by the ability to pay.
The Ministry of Health also launched a national program for health that integrates efforts for diabetes prevention, education, and control along with a system of primary health clinics focused on the treatment of obesity, diabetes mellitus, high cholesterol, and high blood pressure, with an interdisciplinary team. These clinics developed improved guidelines for the prevention, detection, and control of NCDs with behavioral components. They also use technology to optimize attention and improve monitoring and evaluation.
Therefore, owing to the increasing diabetes prevalence and government support initiatives the studied market is anticipated to witness growth over the analysis period.
The sensors segment is expected to witness the highest growth rate over the forecast period
Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose Monitoring. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.
Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies have been reported to have high potential in continuous glucose sensing, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, presents a much longer lifespan in comparison with electrochemical sensors.
Diabetes mellitus in Mexico has been declared a national emergency, and the country has designed various control programs, such as the National Strategy for the Prevention and Control of Overweight, Obesity, and Diabetes, based on public health, medical care, and fiscal and regulatory policies. Government actions to control diabetes include communication programs to raise awareness about the disease and the benefits of healthy weight, diet, and physical activity, self-care diabetes campaigns, guidelines to diagnose and control diabetes, development of self-support groups for diabetic patients, and the development of a National Health Card for adults. Such initiatives are expected to create awareness among the people regarding the monitoring and control of diabetes, thereby enhancing the market prospects in the years to come.
The aforementioned factors are set to boost market growth.
Competitive Landscape
The Mexican continuous glucose monitoring market is consolidated, with few significant players. There have been constant innovations driven by manufacturers such as Abbott, Dexcom, and Medtronic while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
Mexico Continuous Glucose Monitoring Industry Leaders
-
Abbott
-
Dexcom
-
Medtronic
-
Ascensia
-
GlySens
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- April 2023: The FDA approved the MiniMed 780G System for modifications to the SmartGuard (SG) Technology and for expanding the indications for use to include the Guardian 4 Sensor. The MiniMed 780G system is intended for continuous delivery of basal insulin (background insulin) at selectable rates and the administration of insulin boluses (a single large dose of medicine) at a selectable amount for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin.
- March 2023: Abbott announced that the Food and Drug Administration (FDA) cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.
Mexico Continuous Glucose Monitoring Market Report Scope
Achieving optimum glycemic results can be very difficult without frequent monitoring of blood glucose levels. A continuous glucose monitor tracks blood sugar levels 24 hours a day. It collects readings automatically every five to 15 minutes and detects trends and patterns to provide a complete picture of diabetes.
The Mexican continuous glucose monitoring market is segmented into components (sensors) and durables (receivers and transmitters).
The report offers the value (in USD) and volume (in units) for the above segments.
| Sensors |
| Durables |
| Component | Sensors |
| Durables |
Key Questions Answered in the Report
How big is the Mexico Continuous Glucose Monitoring Market?
The Mexico Continuous Glucose Monitoring Market size is expected to reach USD 187.11 million in 2027 and grow at a CAGR of 11.99% to reach USD 329.61 million by 2032.
What is the current Mexico Continuous Glucose Monitoring Market size?
In 2026, the Mexico Continuous Glucose Monitoring Market size is expected to reach USD 167.08 million.
Who are the key players in Mexico Continuous Glucose Monitoring Market?
Abbott, Dexcom, Medtronic, Ascensia and GlySens are the major companies operating in the Mexico Continuous Glucose Monitoring Market.
What years does this Mexico Continuous Glucose Monitoring Market cover, and what was the market size in 2024?
In 2025, the Mexico Continuous Glucose Monitoring Market size was estimated at USD 149.19 million. The report covers the Mexico Continuous Glucose Monitoring Market historical market size for years: 2021, 2022, 2023, 2024, and 2025. The report also forecasts the Mexico Continuous Glucose Monitoring Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.